Melanoma is an important public health problem, and its incidence is increasing worldwide. The disease status of regional lymph nodes is the most important prognostic factor in early-stage melanoma patients. Sentinel lymph node biopsy (SLNB) was introduced in the early 1990s as a less invasive procedure than complete lymph node dissection to allow histopathologic evaluation of the "sentinel lymph node" (SLN), which is the first node along the lymphatic pathway from a primary tumor. Sentinel lymph node biopsy has minimal complication risks compared with standard complete lymph node dissection. Currently, SLNB is the accepted method for staging patients with clinically node-negative cutaneous melanoma and provides the most powerful prognostic information by evaluating the nodal basin status. The current practice of SLNB consists of the injection of 99m Tc-labeled radiopharmaceutical, preoperative lymphoscintigraphy with the possibility of using the SPECT/CT hybrid imaging, and intraoperative SLN localization using a handheld gamma probe with or without the use of blue dye. Recently, the SLN localization and detection have been enhanced with the use of new tracers and new intraoperative devices, which have demonstrated to be particularly useful in melanomas of the head and neck region and in area of complex anatomy. Despite these important advances in the technology and the increasing experience in SLN mapping, major research centers have reported a false-negative rate higher than 15%. This relatively high false-negative rate, greater than those reported in the initial validation studies, points out the importance for the nuclear medicine community to continuously improve their knowledge on the biological behavior of melanoma and to improve the technical aspects that may allow more precise staging. For the SLNB procedure to be accurate, it is of critical importance that all "true" SLNs are identified and removed for examination. The aim of this article is to provide general information about the SLNB procedure in clinical practice highlighting the importance of standardization and accuracy of SLN identification in the light of the most recent technical innovations.
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Key Words: melanoma, sentinel lymph node biopsy, standardized technical approach, radiopharmaceuticals, clinical advances (Clin Nucl Med 2016;41: e498-e507) M elanoma is a global health problem, and its incidence is increasing worldwide. 1 In the recent years in Europe, the estimated annual incidence of melanoma was 9/100,000 and the mortality was 2.3/100,000. 2 Regional lymph nodes are the most common site of melanoma metastases and are often the first site involved with metastatic disease (American Joint Committee on Cancer [AJCC] stage III) before the spreading of disease to distant sites (AJCC IV stage). 3 The presence or absence of nodal disease, even in the form of micrometastases, has been found to be the most important prognostic factor in early-stage melanoma patients (AJCC stage I-II). 4 Because physical examination and imaging modalities are insufficiently sensitive to detect occult (microscopic) diseases, a histopathological assessment of lymph nodes is necessary for early detection of melanoma metastasis. Before the advent of SLNB, complete lymph node dissection (CLND) was routinely performed to stage clinically node-negative melanoma patients. However, the risk of nodal metastatic involvement increases with increasing Breslow thickness and most patients with thin (≤1 mm depth) or intermediate thickness (>1.00 mm ≤ 4.00 mm) will not harbor nodal metastasis. 5, 6 Therefore, CLND has exposed many patients to unnecessary risks of short-and long-term complications such as lymphedema, hematoma, seroma, wound infection, nerve dysfunction, pain, functional deficit, and swelling. Moreover, several prospective trials have shown that CLND has not improved survival. 7, 8 In the early 1990s, Morton et al 9 introduced the technique of SLNB as a less invasive method to allow evaluation of the lymph node status. Indeed, SLNB has minimal complication risks compared with CLND. [10] [11] [12] The procedure of SLNB is based on the paradigm that lymphatic drainage from the site of cutaneous melanoma takes place in an "orderly" manner, involving first a single or few nodes, namely, SLNs, then the remaining nodes of a specific lymphatic basin. Thus, the SLN is defined as a node receiving lymphatic drainage directly from the primary tumor, which acts as the first-line filter for tumor cells detaching from the primary lesion 13 (Fig. 1 ). If the SLN is histologically negative for metastases, the remaining lymph nodes in the basin are unlikely to harbor disease. 3, 14, 15 Therefore, by examining the lymph node that is at the greatest risk of containing metastases, the SLNs, it is possible to perform accurate lymph node staging so as to avoid the potential complications of CLND if not necessary. Moreover, by guiding the pathologist to analyze more intensively few lymph nodes, the SLNB procedure also increases the identification of nodal (micro)metastases and thus enables clinicians to identify patients with occult nodal metastases that would otherwise take months or years to become clinically palpable. Therefore, despite the less invasive nature of an SLNB, the staging data obtained from an SLNB can actually be more accurate than CLND. In the course of the years, SLNB has been validated and is now widely accepted as the standard method in the TNM system for staging of clinically localized cutaneous melanoma. 4, 16, 17 The SLNB procedure is an excellent staging technique and provides a powerful prognostic information by defining the nodal basin status. Sentinel lymph node biopsy identifies 20% of patients with clinically occult nodal metastasis at diagnosis, which is the most important independent predictor of survival. Therefore, SLNB improves the outcomes of patients with occult disease by preventing the development of clinical regional node involvement and allows also to identify patients with pathologically node-negative disease who would not benefit from CLND. 18, 19 Currently, CLND is recommended only for patients with positive SLN, whereas those with negative SLN require surveillance and CLND in the event of a nodal recurrence. 20 All these features have favored the diffusion of routine SLNB worldwide like no previous procedure in oncologic surgery. Nevertheless, SLNB large-scale adoption has raised some problems with respect to high variability in the false-negative rates (FNRs) reported by the literature, greater than those reported in the initial validation studies. Morton et al 9 initially performed routine CLND for validation of the SLNB procedure in melanoma patients and found an encouraging low FNR of less than 1%. Subsequently, the routine CLND was abandoned as validation method, and the false-negative cases were estimated on the basis of detection of tumor recurrence in a nodal basin in which the SLN had been previously classified as metastasis-free. Several large-scale worldwide studies based on this approach have revealed a relatively high FNR, ranging between 5.6% and 21%. 18, [21] [22] [23] [24] [25] Increase in the FNR during clinical and instrumental follow-up over the years indicates that in some patients occult lymph node disease was probably not correctly identified at diagnosis and that micrometastasis has progressed over the years to palpable disease. In addition to melanoma biological behavior and to clinical patient characteristics, which cannot be modified, the procedure of SLNB may not have been performed correctly; some sources of failure may have occurred and eventually the "true" SLN may be misidentified or not removed. Indeed, the concept of SLN is a biological rather than anatomical concept. The true biological SLN is the node that has the highest probability of harboring metastases and is not necessarily the closest to the tumor or the most evident at preoperative imaging and even the most radioactive in the surgical field. 26, 27 In this regard, the main purposes of this article are to define the clinical applications of the SLNB and to describe all steps of the technique in the light of the most recent technological innovation, especially from the nuclear medicine point of view, to permit a more specific identification of the true SLNs and to decrease the FNR.
INDICATIONS AND CONTRAINDICATIONS
Sentinel lymph node biopsy should preferably be performed after diagnostic excision of the melanoma and histological confirmation of the diagnosis. It should be combined with 1 to 2 cm local excision margins depending on the depth of the melanoma. Breslow thickness is the most important factor determining the indication for SLNB. International guidelines agree on the fact that SLNB is indicated for the staging of clinically lymph node-negative melanoma of intermediate Breslow thickness (1.01-4 mm), while the appropriate course of action in the case of thin (≤1 mm) and thick (>4 mm) melanoma remains a matter of controversy. [28] [29] [30] [31] The Multicenter Selective Lymphadenectomy Trial demonstrated that in patients with intermediate-thickness cutaneous melanoma, SLNB-based management prolongs not only disease-free survival (DFS), but also distant DFS and melanoma-specific overall survival (OS). 19 Sentinel lymph node biopsy remains controversial in patients with thick melanoma because there is a high rate of both regional and systemic occult disease at the time of diagnosis. In this population, SLNB may not provide significant prognostic information, and the benefit of the early treatment of lymph node metastases in terms of OS was not shown in Multicenter Selective Lymphadenectomy Trial. 19 According to the American Society of Clinical Oncology and the Society of Surgical Oncology, the use of SLNB may be recommended for staging purposes and for facilitating regional disease control. Sentinel lymph node biopsy should be offered in selected patients with thin melanoma and high-risk features, when the benefits of pathologic staging may outweigh the potential risks of the procedure. Such adverse factors may include ulceration or mitotic rate ≥ 1/mm 2 , especially in the subgroup of patients with melanomas 0.75 to 0.99 mm in Breslow thickness. 4, 29, 30, 32 The European Association of Nuclear Medicine (EANM) guidelines recommend SLNB in thin melanoma also in the presence of more than 50% to 75% regression of the whole pigmented lesion. According to the National Comprehensive Cancer Network clinical practice guidelines, SLNB is not recommended for primary melanoma ≤ 0.75 mm thick, unless there is significant uncertainty about the adequacy of microstaging. 28 Sentinel lymph node biopsy can also be considered in patients with a suspected intermediated thickness tumor that cannot be reliably assessed for reasons such as shave biopsy, or when cryotherapy, laser, or cauterization have been performed on the same lesion before the diagnosis of melanoma. 30 Contraindications to SLNB in melanoma patients include poor general health status, known local or systemic spread of disease, and previous extensive surgery in the region of the primary tumor or of the targeted lymph node basin. Sentinel lymph node biopsy should not be offered to patients presenting with primary melanoma and satellitosis or "in-transit" metastases (intralymphatic metastases between the primary lesion and the nodal basin) because they are already at stage III and the information offered by SLNB will not change the prognosis and the treatment approach. 30 
TECHNICAL ASPECTS

Radiopharmaceuticals
Lymphatic drainage can be studied with radiopharmaceuticals, blue dyes, or both. The initial technique developed by Morton et al used blue dye alone injected at the site of the primary melanoma. The blue-stained draining lymphatic channel was followed surgically until the blue SLN was reached, with an SLN identification rate of 82%. 9 Subsequently, radiolabeled colloids were used to enable the preoperative identification of SLN by lymphoscintigraphy and the intraoperative identification of SLN by a handheld gamma probe. Today, most SLNs are identified by using radiotracer with or without blue dye, with an identification rate ranging from 98% to 99%. 33 The most common radiotracers include 99m Tc-sulfur colloid (particle size, 15-5000 nm), 99m Tc-nanocolloid (5-100 nm), and 99m Tc-antimony trisulfide (3-30 nm). 30 After interstitial administration, the radiotracers migrate along the lymphatic system with a kinetic distribution inversely proportional to the size of the radiocolloid. The radiotracer is retained in the first lymph node (or nodes) encountered along the lymphatic pathway because of the clearing function of the macrophages based on active phagocytosis. 34 A fraction of the radiopharmaceutical often moves on to second-and third-echelon nodes downstream, so that multiple radioactive lymph nodes in the same lymphatic basin are detected by lymphoscintigraphy or by intraoperative gamma probe counting. Consequently, there are often some technical difficulties in the identification of the true SLN among all these radioactive lymph nodes in the surgical field. Furthermore, when a node is massively involved with metastasis, the biologic clearing mechanism of phagocytosis is lost, so that massive tumor invasion can prevent the SLN uptake of injected radiocolloids. 35 Recently, 99m Tc-tilmanocept (Lymphoseek) has been approved by the US Food and Drug Administration for lymphatic mapping in breast cancer, melanoma, oral squamous cell carcinoma, and other solid tumors. 99m Tctilmanocept is a receptor-binding radiopharmaceutical consisting of multiple units of mannose that serve as a ligand for mannose receptors (CD206) expressed by reticuloendothelial cells in lymph nodes. Because of its small particles size (7 nm) and its selective binding to mannose receptors, 99m Tc-tilmanocept exhibits advantages over radiocolloids, including rapid clearance of the injection site, high SLN extraction, and low distal node accumulation. 36 New techniques are currently being developed by using fluorescent or hybrid tracers. Owing to the limited visibility through the skin or overlying tissue, the limited sensitivity of blue dye detection was one of the main reasons for introducing (near-infrared) fluorescent agents, in particular, indocyanine green (ICG) as an alternative for optical imaging for SLNB. 37 After intradermal injection, ICG flows along with the lymph fluid and accumulates in the SLN within minutes, enabling real-time detection of SLN(s) as fluorescent hot spots. Near-infrared dyes are invisible to the human eye and can only be visualized using a dedicated near-infrared fluorescence camera system. 38 The improved tissue penetration of the fluorescent label over blue dye and the better spatial resolution that can be obtained with respect to the gamma tracing modalities help increase the identification of the SLN, especially in areas with a complex anatomy or in areas with the near-injection site SLN. However, in complex anatomy areas, such as the head-neck region, radiotracers remain the standard of care because only radioactive tracers allow for preoperative imaging (SPECT/CT), thus enabling visualization of the radioactive hot spots (SLN) and preoperative planning of the most optimal surgical approach toward the SLN. To take advantage of the properties of radiotracers for preoperative SLN mapping and the high detection sensitivity of near-infrared fluorescence dyes during the operation, hybrid tracers containing both a radioactive and a fluorescence label have been introduced recently. To date, ICG-99m Tc-nanocolloid has been the most widely used hybrid tracer for SLNB. [39] [40] [41] [42] [43] With this development, the strengths of radiotracers, such as lymph node retention for many hours, preoperative imaging, and localization of deeply located nodes, are complemented by detailed real-time fluorescence guidance so as to better localize the true SLN and to reduce the FNR. Indeed, the fluorescence signature of ICG-99m Tc-nanocolloid was found to be of additional value for the detection of SLN(s) close to the injection sites, SLN(s) located in the head-neck region, and SLN(s) failing to accumulate blue dye. 40, [44] [45] [46] Finally, the administration of superparamagnetic iron oxide particles (SPIOs with a particle size of 60 nm, Sienna+) is an alternative, nonisotopic, and nonoptical, method for detecting the SLN, whose relevance for SLNB in melanoma needs to be further investigated. 47 
Radiopharmaceutical Injection
The radiotracer should be administered with 4 or more intradermal injections around the primary tumor or the excisional biopsy site so that drainage from that site can actually reflect dermal lymphatic drainage from that specific area of the skin. Intradermal injections are recommended because melanocytes are located between the dermis and the epidermis and cancer cells initially grow in this space, before spreading elsewhere. According to the EANM guidelines, the radiotracer should be administered in wheals within 1 cm from the melanoma or the excisional biopsy scar. 30 A larger distance from the primary tumor is recommended in the case of hypertrophic or scarred skin. If the area is inflamed and infected, the procedure should be rescheduled until after resolution of the local disease. The injections should be performed using 25-gauge or 27-gauge needles by inserting the needle in a direction as tangent as possible to the skin surface for a few millimeters inside the skin, taking care not to contaminate the patient's skin. The number and specific site of the radiocolloid aliquots to be injected vary according to the anatomic region explored. Indeed, radiotracer administration should be performed in equal deposit around the lesion or surgical scar in patients with melanoma located in the head-neck region and in the trunk because of the ambiguous lymphatic drainage, which may occur both cranially and caudally, as well as across the midline of the body. If the lesion is located in the upper limbs, the lymphatic can be reliably mapped by injecting 1 or 2 aliquots proximal to the scar because lymph flows unidirectionally from the more distal regions (hand and forearm) to the proximal regions (arms and axilla). In the lower limbs, the tracer is injected only proximal to lesions in the foot and leg because lymph flows unidirectionally but proximal and distal to lesions in the thigh because lymph can drain either proximally toward the groin or distally toward lymph nodes in the popliteal region. 48 The radiopharmaceutical should be administered the day before surgery or alternatively on the same day (2-day or 1-day protocol). The injected activity varies from approximately 5 MBq up to 120 MBq depending on the time between lymphoscintigraphy and surgery and the volume injected needs to be small (0.1-0.2 mL per aliquot) to avoid lymphatic collapse. 30 
Preoperative Imaging
After injection, lymphatic imaging is performed to assess appropriate radiotracer drainage and uptake. The main benefit of lymphoscintigraphy is that it reflects the actual functional state of lymphatic drainage in the individual patient with cutaneous melanoma. Lymphoscintigraphy allows to visualize the lymphatic drainage of the specific region of the skin where the melanoma is located, and it identifies all the lymph node basins at greater risk of metastases, including those in unexpected location, for each of which is possible to identify the SLN(s) (Fig. 2) . [49] [50] [51] Furthermore, lymphoscintigraphy allows the identification and biopsy of in-transit nodes, which should be removed along with the SLN because they may be the only sites of nodal metastasis. 52 All possible drainage regions need to be covered during image acquisition to localize unpredictable lymphatic drainage patterns. A large FOV gamma camera should be used, equipped with a high-resolution collimator having a 10% window centered on the 140-keV energy peak of 99m Tc. A dual-head gamma camera is preferred to reduce examination time. Dynamic lymphoscintigraphy (30 minutes, 1 frame per minute in a 128 Â 128 matrix), recorded immediately after radiopharmaceutical injection, is essential for both identification of all regional lymphatic basins and differentiation of the true SLN (first-echelon node) from non-SLN (second-echelon lymph nodes) situated on the same lymphatic path. After dynamic series, static early images (5 minutes with a 128 Â 128 matrix) are obtained over the regional basin in which the SLN is visualized or expected. In the melanoma of the trunk, bilateral static images of the axilla, trunk, and groin are usually necessary. Static images can be repeated at 2 to 6 hours after injection, when the nodes are not clearly depicted or even just before the operation. Finally, the site of each SLN can be marked on the overlying skin using a 57 Co flood source to assist the surgeon to localize the SLN. 48 According to the EANM guidelines, dynamic lymphoscintigraphy is recommended for detection of SLNs in both the head-neck and the trunk melanoma to reveal the progression of lymphatic flow and to outline the draining lymphatic basins. However, the dynamic series should be acquired whenever possible as it facilitates image interpretation and in-transit nodes identification. 30, 53 The study carried out in the nuclear medicine department is completed by further confirming of the exact location of the SLN(s) by external counting with the handheld gamma probe.
SPECT/CT
SPECT/CT might be useful in localizing SLNs, identifying additional SLNs and planning surgery. Lymphoscintigraphy can provide a roadmap for surgeons, but 3-dimensional (3D) imaging with SPECT/CT has shown to be superior to planar imaging to detect SLNs, especially in complex anatomical areas, such as the head-neck region and the trunk (Fig. 3) . Indeed, SPECT/CT provides functional information from SPECT, which can be combined with the morphological information of CT. The main advantages of SPECT/CT include more accurate anatomical localization of SLNs, detection of additional SLNs not seen on planar imaging, and reduction of misinterpretation of images (eg, skin contamination or injection site). CT is also used to correct the SPECT signal for tissue attenuation and scattering, thus enabling the visualization of poorly detectable nodes on planar images because too close to the injection site (the so-called shine-through phenomenon), or overlaid by fatty tissue (eg, in obese patients or in areas of deep lymphatic drainage). 54 SPECT/CT thus facilitates and can modify the surgical procedure providing valuable information concerning the anatomic relationship of the SLNs with the neighboring vascular structures and surrounding tissues. In a recent multicenter study, it has been demonstrated that SPECT/CT detects more SLNs than planar images, leading to surgical adjustments in a considerable number of patients. 55 In accordance with international guidelines, the authors recommended SPECT/CT in all patients with melanoma of the head-neck or trunk and in melanoma patients with unexpected drainage on planar images. According to the EANM guidelines, SPECT/CT should also be performed in the groin and axillary area as it reduces the misinterpretation of image. 30 It is important to consider that SPECT/CT does not replace lymphoscintigraphy, it has higher costs, it increases camera time with related patient discomfort, and it delivers a small, but nonnegligible radiation dose. It should be considered as a complementary modality that provides detailed anatomical information. However, this additional information may have an impact on surgical management by improving preoperative planning, excluding false-positive sites of radiopharmaceutical uptake (eg, skin contamination, stasis of the radiotracer along the lymphatic pathways), reducing surgical morbidity, and influencing patient outcome. 56, 57 SPECT/CT overcomes the limitations of planar imaging, especially in the head and neck. 58, 59 Indeed, SLNB is technically more difficult to explore in the head-neck region because the lymph nodes are often small and close to the injection site. Moreover, distinguishing whether the SLN is deep or superficial or located inside or just outside the parotid gland is important. Thanks to enhanced resolution and improved anatomic localization of SLNs, SPECT/CT imaging allows more accurate lymphatic mapping with the detection of additional SLNs in more than one third of the procedure and it reduces morbidity from the SLNB procedure. 56, 60 SPECT acquisition parameters may include a 360-degree orbit with 180-degree or 90-degree detector geometry, 128 Â 128 matrix size, and 3-degree angle step with 20 to 25 s/ frame with iterative reconstruction algorithms. CT is acquired by using low-dose scan (40 mA) without contrast enhancement because it is principally oriented to the anatomical localization of SLNs. By means of dedicated software, the data obtained with (Fig. 4 ).
Intraoperative Procedure
Intraoperative SLN detection is based on gamma probe acoustical detection. To increase the sensitivity of SLNB, the injection of blue dye may be added in the surgical setting and it is recommended that all blue staining nodes should be harvested. By means of the gamma probe, the area with the highest activity (counts per second) in each lymphatic basin is identified and correlated with the skin marker that has been positioned during lymphoscintigraphy. Furthermore, ex vivo counts are taken over the site of the radiopharmaceutical injection and along the lymphatic channels draining to the lymphatic basins. After incision over the area with the highest activity, in vivo radioactivity is measured, moving slowly the gamma probe in the surgical bed. Radioactive lymph nodes are identified by comparison with background activity, which is defined as the average count rates of the surrounding non-SLNs and lymph node basin. 48 After SLN identification through both in vivo and ex vivo counting, the gamma probe is used to measure the residual activity in the lymphatic basins to identify and remove additional radioactive nodes. In this regard, multiple radioactive lymph nodes are often detected in the same lymphatic basin and it is not always clear whether all these radioactive lymph nodes represent true SLNs or whether they are simply second-echelon nodes. International guidelines lack a unique definition for the optimal criteria for radioactive SLNs removal 30 but is mandatory, achieving a consensus on the radioactive counting rate threshold to guide the surgeon in the identification of those lymph nodes with the highest probability of harboring metastases, avoiding the unnecessary removal of radioactive non-SLNs and reducing the morbidity associated with the procedure. Different approaches have been developed according to the level of radioactivity detected within the nodes so as to identify the correct SLN, when multiple nodes have accumulated the radiopharmaceutical. Some authors base SLN identification on the absolute number of counts in the nodes, while others consider the ratio of the in vivo or ex vivo radioactive counts in the node relative to background or to neighboring non-SLNs. 61, 62 According to McMasters et al, 63 it is recommended that all nodes that are 10% or higher than the ex vivo radioactive count of the hottest SLN should be harvested. Because the 10% threshold could lead to the superfluous removal of multiple non-SLNs, some authors suggested that such a threshold could, for example, be increased to 20%. 61 In this regard, Manca et al 64 demonstrated that after a long-term follow-up a 20% threshold should be applied for optimal detection of nodal metastases in patients with cutaneous melanoma. The surgeon should also examine the region of interest to identify palpable lymph nodes that ought to be removed even if they are not radioactive or blue. 30 
Intraoperative Imaging
Recently, new devices have been introduced in combination with the conventional handheld gamma probe to improve the intraoperative detection of SLNs. 65 Indeed, the signal of the injection area can make difficult to localize nearby SLNs, and deeply located SLNs may be missed because of tissue attenuation. Portable gamma cameras have been developed for intraoperative planar imaging. These portable devices enable visual real-time feedback when localizing SLNs and confirm their successful resection. 66, 67 Vermeeren et al demonstrated that intraoperative identification of SLNs in the head and neck region with a portable gamma camera is feasible and can detect additional lymph nodes in 24% of patients compared with preoperative scintigraphy. 68, 69 Moreover, portable gamma cameras have been recently combined with fluorescence cameras for simultaneous gamma and fluorescent SLN detection by using hybrid tracers. 70 This new technology may contribute to SLN localization in complex anatomic areas, such as the head-neck region. 71 In addition, the Declipse system (SurgicEye, München, Germany), or socalled free-hand SPECT (fhSPECT), has been introduced to allow for intraoperative 3D navigation to radioactive targets such as SLNs. 72 The 3D tomographic modality is based on the integration of data obtained with a conventional handheld gamma probe and an infrared optical tracking system with reference targets on the patients and in the gamma detection device. 73 While the surgeon is moving, the "freehand" gamma probe over the region of interest, the position of the patient, and the gamma probe are continuously recorded by the tracking system, thus allowing for direct visualization of the distribution of radioactivity in the surgical field and providing accurate lesion depth measurement. The detection of gamma emission from different angles improves the identification of SLNs with low tracer accumulation and deep-lying nodes, especially in complex anatomic areas. 74, 75 FhSPECT might also simplify the planning of the incision, an important element due to the fact that skin marking is not always helpful because of the different position of the patient preoperatively and intraoperatively. Also useful are the integration of preoperative SPECT/CT into the fhSPECT technology 76 and the real-time fusion of fhSPECT and ultrasound 77 for anatomical coregistration of SLN(s). Although it has been shown that fhSPECT improves SLN identification rates in melanoma patients, 78, 79 further prospective studies are necessary to evaluate the field of indication for this novel intraoperative device and to investigate its cost-effectiveness.
Future Scenarios
Nowadays, with the development of intraoperative imaging and hybrid tracers, a new scenario is emerging in radio-guided surgery. Indeed, the integration of anatomical and functional imaging offered by nuclear medicine procedures, together with the improvement of the CT component of SPECT/CT, enables the creation of the so-called mixed reality surgery, also defined as "augmented reality" surgery. In the mixed reality, the preoperative virtual SPECT/CT images are transferred to the operating room with the use of a tracked protocol to create a 3D virtual space through which the surgeon can move easily to perform the surgical procedures. By the integration of preoperative 3D imaging, intraoperative 3D navigation, and optical real-time feed-back, it is therefore possible to visualize the target lesions in real-time to confirm the navigation accuracy and to facilitate excision during minimally invasive SLNB procedures. All these technological advances, principally oriented to optimize surgery in complex anatomical areas, such as in the head-neck region, will also play an increasing role in the future extension of the SLNB in oncologic surgery. 80, 81 
DISCUSSION
Sentinel lymph node biopsy is the standard of care in the management of early-stage melanoma patients. 4, 29, 30 The technique of lymphatic mapping and SLNB provides accurate staging and prognostic information with minimal morbidity and can be used to identify regional node-negative patients who would not benefit from CLND. 82 The presence of nodal metastases has been found to be the most important prognostic factor in early-stage melanoma, particularly in intermediate-thickness melanoma. 4 By mapping the regional lymph system around the primary tumor and tracing the lymphatic flow, SLNB determines the lymph node or nodes where the cancer is most likely to spread first, enabling an accurate histologic analysis of the entire local lymphatic basin. Sentinel lymph node biopsy greatly facilitates early identification of nodal metastases relative to clinical examination or imaging studies and has led to a dramatic shift in the prognosis of patients with metastatic melanoma to regional lymph nodes. 4 Early detection of melanoma metastases to the lymph nodes allows for early control of regional disease because nodal micrometastases, if left untreated, may develop into macrometastases, which ultimately and theorically may promote the development of metastatic distant disease. 83, 84 Indeed, in addition to its significant role in accurate regional nodal staging and prognosis, important goals of the SLNB procedure include improved regional disease control and possible survival benefit. The final report of the MSLT-I showed that SLNB-based management prolongs DFS for all patients and prolongs distant DFS and melanoma-specific OS for patients with nodal metastases from intermediate-thickness melanomas. Therefore, considering that immediate regional CLND for a positive SLN may improve regional disease control and survival and recent emergence of immunotherapies and novel targeted treatments for stage III melanoma patients, it is mandatory to achieve a correct staging to identify patients that could benefit from surgery and/or adjuvant therapy. Sentinel lymph node biopsy enables accurate nodal staging, enhanced regional disease control, and improved survival, but its reliability depends on the accurate visualization and identification of the true SLN(s). 26, 27 Recently, several large-scale studies from prominent institutions and collaborative groups worldwide have reported FNRs, usually identified by local lymph node recurrence after a negative SLNB, varying between 5.6% and 21%. 18, 25, 85 Taking into account the important clinical implications of the SLNB procedure, there is legitimate concern about such relatively high FNRs because they are greater than those reported initially by early validation studies based on CLND performed at the same time when performing SLNB. 9 The FNR was inversely associated with the proportion of patients successfully mapped and positively associated with duration of follow-up. 24 These data point out that SLNB is not a simple biopsy procedure. Technical factors are important to avoid leaving in place lymph nodes containing metastatic cells that would progress onto clinically detectable disease. Therefore, it is fundamental to eliminate those critical areas of variability that may lead to error to allow the surgical removal and analysis of only the true SLN(s). 64 The success of SLN identification is largely the result of the strict standardization of the technique, and technical aspects are fundamental for accurate nodal staging. 86 An essential prerequisite for a successful SLNB procedure is an accurate map of the pattern of lymphatic drainage from the primary tumor site in each patient. 87 According to current practice guidelines, the standard SLNB preoperative protocols for cutaneous melanoma comprise dynamic, early, and delayed static images. 30 Preoperative lymphoscintigraphy is performed after radiotracer administration to establish a roadmap for the surgeon identifying all regional lymphatic basins that are at risk and to facilitate intraoperative identification of the true SLN. The SLN is usually located in a regional lymphatic basin, but lymphatic drainage from the skin is highly variable from patient to patient, even when the same region of the body is being examined. Lymphoscintigraphy is essential for accurate SLNB, especially for head and neck melanomas, because they are technically more difficult due to the complex and less predictable lymphatic drainage in this area. 88 Each physician must be familiar with the common lymphatic drainage patterns for different areas of the body, aberrant routes of the lymphatic, and aberrant locations of the SLN. 89 Imaging must be timed to avoid missing true SLN(s) or identifying non-SLNs as SLN(s). 90, 91 Indeed, lymphoscintigraphy and intraoperative gamma counting often identify multiple radioactive lymph nodes in the same lymphatic basin, and if progression of the radiocolloid is not appropriately monitoring during lymphoscintigraphy (eg, by dynamic recording), it is not always clear which of these radioactive lymph nodes is the true SLN. Combined application of blue dye and gamma probe improves sensitivity of the SLNB procedure in the surgical setting, 30 but the criteria for the surgical SLN(s) detection represent an important key area of standardization. It is to be recommended that the nuclear medicine community reaches a consensus on the optimal radioactive counting threshold to better guide the surgeon in identifying the true SLN(s), considering that not all radioactive nodes are necessarily SLN(s). However, such consensus is technically challenging to achieve because the number of radioactive hot nodes depends on the radiocolloid agent used and on the time between its injection and subsequent surgery. 62 In this regard, 99m Tc-tilmanocept was specifically developed to overcome radiocolloid limitations thanks to its tight receptor binding within lymph nodes. Its quickly injection site clearance, high SLN extraction, and low distal node accumulation may help to further improve the accuracy of SLNB. 36, 92 For a better anatomical localization of the SLN, international guidelines recommended the routine use of SPECT/ CT. 30 Preoperative 3D imaging with SPECT/CT provides exact preoperative localization of SLN(s) as well as higher detection rates and should thus be used for preoperative planning and intraoperative decision making, particularly in region of complex anatomy, such as the trunk and the head-neck. [93] [94] [95] It is possible to obtain a better anatomical overview of the anatomotopographic coordinates of SLN(s) by using volume rendering for 3D display with different colors assigned to anatomical structures. Joining functional imaging and anatomical imaging not only contributes to better depiction of the true SLN to be removed, but also enables subsequent intraoperative guidance through the use of gamma probes and minimizes the surgical invasiveness of the procedure. Moreover, the use of portable intraoperative gamma cameras capable of offering imaging guidance during surgery further contributes to direct surgical exploration and also allows real-time monitoring of the completeness of SLN removal. 66 Intraoperative imaging can be compared with preoperative images to localize nodes and distinguish between first true SLN and second-tier radioactive nodes. In some cases, intense tracer uptake at the site of the SLN on preoperative images corresponds to a cluster of SLNs and imaging after excision of the first hot SLN can reveal the remaining SLN(s). 68 The 3D fhSPECT is another intraoperative imaging technology, which allows the surgeon to generate an intraoperative 3D SPECT image, scanning the area of interest in 3 orthogonal directions by means of a conventional gamma probe. The fhSPECT enables the surgeon to visualize the SLN(s) with regard to the current patient position and to virtually navigate the gamma probe toward the SLN(s). All these intraoperative imaging devices are helpful for SLNB in cutaneous melanoma, especially in the head and neck area, in the very close proximity of the radiotracer injection site, or when difficult-toretrieve in-transit SLNs are depicted. However, further technical optimization of these modalities is required before these technological advances can become clinical practice. Recently, new tracers have been developed for use in both lymphoscintigraphy and intraoperative SLN localization to improve the accuracy of SLN identification and removal. The use of the near-infrared fluorescence component instead of blue dye as the optical tracer offers more effective SLN identification, especially for SLN(s) near the injection site and in the head and neck. 45 Moreover, the introduction of hybrid tracers, such as ICG-99m Tc-nanocolloid, which combine the advantages of optical and radioguided SLN detection, could potentially be of great value in critical anatomical structures. 40, 41, 96 Preoperative and intraoperative imaging, together with the real-time information on depth and the incorporation of fluorescence imaging into the daily used radioguidance technologies, opens an entire new line of research in oncologic surgery by providing a real-time "mixed reality" roadmap in the operation theater, which may help to further improve the detection of the true SLN(s) and to reduce the FNR.
CONCLUSIONS
Sentinel lymph node biopsy has revolutionized the cutaneous melanoma management and the technical aspects of the procedure continue to evolve and to improve. Current technology enables the exact location of each SLN to be defined, but it is fundamental to continue to refine and to standardize the procedure. Advances in radiopharmaceuticals and computer technologies as well as data processing make it possible to perform accurate SLN imaging and intraoperative SLN detection. Indeed, after more than 20 years of experience, it is evident that accurate SLN mapping is vital to allow the surgical removal of only the true SLN(s) so as to achieve the full clinical benefits of SLNB in terms of staging, prognosis, DFS and OS.
